Background: Inflammation of the synovial membrane involved in knee osteoarthritis (OA) pathomechanism. Cartilage oligomeric matrix protein (COMP) is a cartilage degradation product that has been considered as a biomarker of OA. Interleukin-6 (IL-6) is an inflammatory mediator involved in the pathogenesis of synovial inflammation in knee OA. This study was conducted to proof whether high level of serum COMP and plasma IL-6 increase the risk of synovial inflammation in knee OA. Methods: This was a case control study to proof about the risk of synovial inflammation in primary knee OA patients who were exposed by high level of circulating serum COMP and plasma IL-6. Every case was matched with his/ her control using pair by pair method (pair-matched). Research data was analyzed using statistic computer software program.
INTRODUCTION
Osteoartritis (OA) is a chronic musculoskeletal disease, represents degeneration of the joint cartilage followed by changes of other joint components. Knee OA is the most common arthritic form in the population. In recent years, attentions of the pathomechanism of knee OA were focused on the inflammation of the synovial membrane.
1 Synovial inflammation may occur in the early stage of OA development, therefore it becomes a potential target for the treatment of knee OA. Unfortunately, the risk factors of synovial inflammation in knee OA have not been fully understood.
Recently ultrasound is widely used for evaluating synovial inflammation in knee OA. Ultrasound reveals an organ dynamically, safe from radiation hazard, relatively inexpensive, sensitive, and valid for detection of synovial thickening and joint effusion. It is more sensitive than clinical examination for detecting synovial thickening and joint effusion which are mostly found in synovial inflammation. 2 Many biomarkers have been proven as a nonconventional risk factor for knee OA, but there were limited data about the risk factor of synovial inflammation in knee OA. Cartilage oligomeric matrix protein (COMP) is a cartilage degradation product that has been considered as a biomarker of OA.
3 Level of COMP in synovial fluid and serum of OA patients was significantly higher than control. 4 Furthermore, interleukin-6 (IL-6) is an inflammatory mediator involved in the pathogenesis of synovial inflammation in knee OA. 5 Serum IL-6 level was significantly higher in OA and rheumatoid arthritis (RA) comparing with its level in normal population. 6 Unfortunately, no adequate data explained regarding the role of high level of circulating COMP and IL-6 in the development of synovial inflammation of knee OA that gave manifestastions as synovial proliferation and or joint effusion. Based on these condition, this study was conducted 
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to proof whether high level of serum COMP and plasma IL-6 increase the risk of synovial inflammation in knee OA.
MATERIALS AND METHODS

Research Subject and Design
This was a case control study to proof about the risk of synovial inflammation in primary knee OA patients who were exposed by high level of circulating serum COMP and plasma IL-6. This study involved 56 cases and 56 controls. Research protocol was summarized in Fig.1 Diagnosis of primary knee OA was based on the American College of Rheumatology (ACR) criteria.
3,4 Severity of knee OA was based on the Kellgren and Lawrence (K-L) classification. Knee pain was measured using 10 cm visual analogue scale (VAS) and classified as mild (VAS 1-3), moderate (VAS 4-6), and severe (VAS 7-10).
Diagnostic criteria of calcium pyrophosphate dihydrate deposition disease (CPPD) or pseudogout was the presence of clinical signs of joint inflammation, associated by knee chondrocalcinosis on radiographic finding. 7 Rheumatoid arthritis criteria was based on ACR/EULAR consensus year of 2010. Diagnosis of acute gout arhtritis was based on ACR consensus year of 1977. As diagnostic criteria of confounding variables, hyperuricemia was defined as serum uric acid level >7 mg/dL 8 and diabetes mellitus (DM) criteria was based on American Diabetes Association 2006. Presence of liver inflammation was defined as more than two times increased of SGOT and SGPT level. Criteria for acute infection was the presence of systemic symptom of acute infection such as fever associated by leukocytosis. Chronic infection was determined by increased level of ESR (Westergreen method). Subjects were also interviewed in order to get information about having knee OA medication. The presence of receiving medication for knee OA was defined as consumed analgesic since three-days before enrollment.
Knee Radiograph and Knee Ultrasound (US)
Knee radiograph was performed using weight bearing anterior-posterior (AP) and lateral projection on extention knee, interpreted by a radiologist, based on definition from Kellgren and Lawrence.
Knee US was perfomed using Sonoace 8000 (Medison®, Korean), liniar transducer, 7.5-10 megahertz (MHz) frequency, B-mode setting.
Knee US-procedure was adapted from EULAR part I, 9 combined with procedure by Karim et al.
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Ultrasound criteria of synovial inflammation was the presence of at least one of these findings:
(1) presence of synovial thickening (nodular or diffuse type); (2) presence of joint effusion. Synovial thickening was defined as ≥ 4 mm synovial thickness, joint effusion was defined as ≥ 4 mm effusion depth. 9 Ultrasound evaluation of synovial thickening and joint effusion was performed in the suprapatellar recess, also in the medial and lateral knee compartment. Intra-rated and inter-rated reliability of knee radiograph interpretation for determining OA grade and knee US interpretation for defining synovial inflammation were obtained from our preliminary unpublished study 10 that involved 20 patients with knee-OA. The study revealed good intra-rated reliability (kappa value 0.86, p<0.05) and inter-rated reliability (kappa value 0.78, p<0.05) in interpreting knee radiographs, instead of evaluating parameters of synovial inflammation such as synovial thickening (intraobserver correlation coefficient: 0.79-0.96, p < 0.05; interobserver correlation coefficient: 0.73-0.87, p < 0.05) and joint effusion (intraobserver correlation 0.8-0.9, p < 0.05, interobserver correlation coefficient: 0.74-0.89, p < 0.05).
Measurement of COMP and IL-6
Serum and plasma samples that collected from subjects were freezed in -70 celcius degree until measurement performed. Serum COMP measurement was performed with monoclonal antibody specific for human COMP (Quantikine, R&D Systemâ, Inc., USA). Plasma IL-6 measurement was performed with monoclonal antibody specific for human IL-6 (Quantikine, R&D Systemâ, Inc., USA). Both of them utilized quantitative sandwich ELISA. Measurement procedures were based on the manufacture's procedures. High level of serum COMP was defined as COMP concentration above the median value, so did high level of plasma IL-6.
Patients' physical activity and diurnal variation 11 also influenced circulating COMP level. Physical activity was controlled by taking rest (patient had to sit down at least 30 minutes after they did physical activity such as walked, ran, or other physical activity) before underwent blood sample collection. For all patients, blood sample collection was done at 8 a.m to 1 p.m in order to get the optimal level of circulating COMP according to its diurnal variation.
Statistical Analysis
Research data was analyzed using statistic computer software program. Numerical data presented as mean ± SD if the data were normally distributed and median (minimum-maximum) if the data were not normally distributed. Crosstab bivariate analysis was done to test the association of high serum level of COMP or high plasma level of IL-6 with the presence of synovial inflammation. Odds Ratio (OR) was calculated as an indicator for determining risk difference between exposed and non-exposed group using McNemar significancy test. Multivariate analysis was done using logistic regression to obtain adjusted Odds Ratio (OR) for high circulating level of COMP and IL-6, by analyzed the influence of BMI, OA severity, score of other joint OA, receiving OA medication, hyperuricemia and DM as covariate variables. All of the statistical analysis was using 95% confidence interval (CI).
RESULTS
There were 56 subjects in case group and 56 subjects in control group, which showed predominantly female subjects in both groups (Table 1) . Knee pain scale of the case group was range from moderate until severe scale, in contrast with control group that mostly suffered from mild scale pain. Knee joint swelling was noted in all of case group. In the control group, ten subjects (17.8%) had asymetrical knee circumference, but they did not meet the criteria for synovial inflammation parameters (all of these subjects only suffered from minimal degree of knee pain, none of them had disturbance in knee range of motion, part of them had asymmetrical knee bony enlargement while palpated). Positive bulging sign was noted in 44 (78.6%) subjects of case group and in four (7.1%) subjects in control group. Although there were four control subjects with positive bulging sign, they did not encounter other clinical parameter for synovial inflammation.
Mean value of synovial thickness and joint effusion depth in the case group were higher than those in the control group (Table 3) , although statistically insignificant (p=0.168 for mean difference of synovial thickness between case and control group, and p= 0.126 for mean difference of joint effusion depth between case and control group). In case and control group, synovial thickening always accompanied by joint effusion ( Table 4 ). The presence of joint effusion in huge amount could cause pain due to its stretching effect. This was probably the reason for the patient looking for medication. Contrary, from all of the US findings, none of subjects showed synovial thickness without joint effusion, which This study noted simultaneous positive clinical and ultrasound finding of synovial inflammation in 56 (100%) subjects in case group. Synovial inflammation ultrasonographically without clinical evident was found in 35 (62.5%) subjects in control group. None of the control group met the clinical criteria of synovial inflammation. Median value of serum COMP level was 201.94 ng/mL and plasma IL-6 was 2.5 pg/mL. Based on median value of serum COMP and plasma IL-6, we identified that high serum COMP level was found in 37 (66.1%) subjects of the case group and 19 (33.9%) subjects of the control group. High plasma IL-6 level was noted in the 35 (62.5%) subjects of the case group and in 21 (37.6%) subjects of the control group. From bivariate analysis, serum level of COMP was a significant risk factor of synovial inflammation in knee OA, which gave risk for having synovial inflammation 5.5 times higher than control group (p < 0.001). Similar result was found for high level of plasma IL-6 which gave risk of synovial inflammation 2.88 times higher than control group (p < 0.05) ( Table 5) .
After analyzed using multivariate analysis, high level of serum COMP and plasma IL-6 was still significantly increased the risk factors for the development of synovial inflammation in knee OA (adjusted-OR = 3, p < 0.05 for high level of serum COMP; and adjusted-OR = 2.7, p <0.05 for high level of plasma IL-6). Instead of high circulating levels of COMP and IL-6, knee OA severity (OR 2.37, p < 0.05) and body mass index (OR 1.16, p < 0.05) also gave significant influences for the presence of synovial inflammation. Receiving oral OA medication, the presence of OA of other joint, hyperuricemia and DM did not give significant influence for the presence of synovial inflammation in knee OA (p > 0.05) ( Table 6 and 7) . OA severity of the right knee 
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DISCUSSION
High serum COMP level was found in most of the knee OA patient with synovial inflammation (66.1%), and only in 33.9% subjects of the control group. This result was consistent with the result of study by Zivanovic et al in 2011, who found significant differences of the serum COMP value between the presence of joint effusion vs no joint effusion (p = 0.03), presence of synovitis vs no synovitis (p = 0.006), also in long and short osteophyte (p<0.001). Unfortunately, the research did not further explored the risk difference between the exposed group vs non-exposed group.
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In this study, high level of serum COMP was significantly proven as a risk factor for the presence of synovial inflammation in knee OA, which gave risk 5.5 times higher than control for suffering from synovial inflammation. After adjusted with other covariate variables, high level of serum COMP was persisted as a significant risk factor for synovial inflammation (adjusted-OR=3, p < 0.05), together with knee OA severity (adjusted-OR=2.37, p < 0.05) and body mass index (adjusted OR=1.16, p < 0.05).
Although different in some parameters, Villim et al 13 reported correlation between serum COMP level with age, synovitis, and interaction of synovitis with knee OA severity, which found that synovitis had the strongest effect to the serum COMP level (r = 0.1587, p < 0.01). Their study only used clinical indicator for determining synovitis and emphasized influence of synovitis to serum COMP level, but it did not proof whether high level of serum COMP was a risk factor for synovial inflammation. It was quite different with this study which determined synovitis by clinical and ultrasound findings, and tried to find the risk factors of synovial inflammation in knee OA.
Synovial inflammation in OA is considered as secondary phenomena that caused by phagocytosis 
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of bone debris or released cartilage matrix macromolecules. 1 Products of cartilage degradation consist of broken particles components, soluble cartilage neo-antigen and microcrystals. Those components released into synovial fluid and phagocyted by sinovial lining macrophage, thus stimulated inflammation of sinovial membrane through synthesis of inflammatory mediators, infiltration of mononuclear cells and vascular hyperplasia. Inflammatory mediators also released from sinovial membrane into sinovial fluid, and on the other hand, there was also diffusion of inflammatory mediators from sinovial fluid to the cartilage. Synovial inflammation also causes excessive production of proteolytic enzymes, which also caused cartilage destruction. These processes produced a vicious circle and subsequently stimulated further cartilage degradation and inflammation process through feed back mechanism.
3,5
Joint effusion may happen as a result of inflammation process in the synovium, which is triggered by the presence of cartilage degradation product (in this case is COMP) in the joint space. Subsequently, COMP may phagocyted by synovial macrophage and causes activation of synovial cells.
3,5 Activated synovial cells may release mast cells and angiogenesis mediators which potentially change the vessels permeability in the synovium, 14 and causes increasing of fluid accumulation in the joint space afterward.
Synovial thickening may occur as a result of increase synoviocyte growth, which is probably influenced by anti-apoptotic effect of COMP. Antiapoptotic effect of COMP is reported through inhibition of caspase-3 activation and induction of inhibitor of apoptosis (IAP) family of the survival protein, such as baculoviral IAP repeat-containing protein-4 (BIRC4) and x-linked inhibitor of apoptosis protein (XIAP). Cartilage oligomeric matrix protein also induces increased level of survivin protein (BIRC5). 15 Released of COMP fragments in the joint space may trigger antiapoptotic process in the synoviocytes, which may stimulates mitotic process of the synoviocytes. Result of this study is getting closer to our theoretic hypothesis postulate that explain about the role of COMP in the synovial inflammation which are detected by US as joint effusion and-or synovial thickening.
This study found that IL-6 also significantly increased the risk of synovial inflammation in knee OA (OR 2.88, p < 0.05) although it had already adjusted with multiple logistic regression (adjusted-OR 2.7, p < 0.05). Several study reported parallel results with this study about involvement of IL-6 in synovitis and general inflammation. Gabay et al 16 reported that there was increase IL-6 concentration in the inflammed area. They also found that IL-6 triggered the activation of B-cell, T-cell and mediated recruitment of inflammatoric cells toward the area of inflammation. Orita et al 17 reported that together with TNF-a, IL-6 was detected in the synovial fluid of the knee OA patients, and IL-6 showed negative correlation with joint stiffness (r = -0.48; p < 0.05). They predicted that TNF-a and IL-6 played a role in the pathogenesis of OA-synovitis through different pathways. 17 To the best of our knowledge, our study is the first study that evaluates about the role of circulating IL-6 in synovial inflammation and also proves that high level of plasma IL-6 significantly increases the risk of synovial inflammation in knee OA.
In the pathogenesis of synovial inflammation, synoviocyte-produced IL-6 can trigger activation of acute phase protein, therefore synovial inflammation commonly associates with acute phase response. In the OA pathogenesis, IL-6 was predicted to have double roles, as a stimulator of inflammatory process and also as a protector throughdown-regulation of catabolic factors which involved in the cartilage degeneration. 18 The role of IL-6 in the synovial inflammation is through increasing angiogenesis by induction of VEGF expression, increasing chemokine production (e.g MCP-1 and IL-8) from endothel, mononuclear cells and fibroblast-like synoviocyte, induction of adhesion molecules (e.g ICAM) in endothel, instead of triggering local inflammation reaction via increasing of inflammatoric cell infiltration that are mediated by several signal transduction pathways.
19
Result of this study is supporting our theoretic hypothesis postulate about the role of IL-6 in the synovial inflammation of knee OA detected by US as joint effusion and or sinovial thickening. As a result of cartilage breakdown, releasing of IL-6 as proinflammatory mediator by synovial cells activates JAK-STAT signal transduction pathway, which subsequently stimulates angiogenesis through increase production of VEGF. 20 Increase VEGF amount in the synovium influences the synovial vascular permeability, 21 protein leakage from synovial vessels and later may cause joint effusion. Synovial thickening in knee OA probably happens as a result of mitogenic effect of IL-6 on synoviocytes. Interleukin-6 actívates JAK-STAT signal transduction pathway that causes activation of hypertrophic regulator and survival genes, 22 and activates PI3K pathway that stimulates cell survival genes and inhibits apoptosis of the synoviocyte.
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Other things that could be proven in this study were the role of knee OA severity and BMI in increasing the risk of synovial inflammation. Knee OA severity increased the risk of synovial inflammation 2.37-2.88 times higher than control (OR= 2.37 as a covariate of high level of serum COMP; p = 0.019, and OR= 2.88 as a covariate of high level of plasma IL-6; p = 0.003, respectively). This result was similar with prior study. Research conducted by D' Agostino et al 9 in the EULAR multicenter research about the prevalence of inflammation in knee OA reported that advanced radiographic OA increased the probability of synovial thickening (OR 2.2; p < 0.0001) and US-detected joint effusion (OR 1.97; p < 0.0001). They concluded that synovitis was more common in the late stage knee OA.
Influence of knee OA severity to synovial inflammation related to the increased of cartilage loss and the amount of cartilage degradation product releasing into the synovial fluid, which subsequently stimulated the secretion of proinflammatory mediators and synovial inflammation. 5 Association of knee OA severity and synovial inflammation was considered a vicious circle, because in the other aspect, synovial inflammation was becoming a risk factor of joint cartilage loss. Roemer et al 24 reported that inflammation activity reflected by joint effusion and synovial thickening correlated with increase of the risk of cartilage loss.
Body mass index also gave significant contribution in increasing the risk of synovial inflammation in knee OA 1.15-1.16 times higher than control (OR = 1.16 as a covariate of high level of serum COMP, p = 0.029; and OR = 1.15 as a covariate of high level of plasma IL-6, p = 0.049; respectively). Recently, obesity was considered as a mild inflammatory stage which is very related to white adipose tissue (WAT). White adipose tissue had known as an origin of classic proinflammatory cytokine and adipokines. Dysfunctional adipocyte may produce proinflammatory adipokine which interacts with osteoblasts, synoviocytes, and chondrocytes through induction of proinflammatory mediator (e.g cytokines, ROS, NO) and cartilage degradation factors (e.g MMP and ADAMTS). Increase IL-6 production influenced by adiponectin may activate synovial fibroblast subsequently 25 and triggers several inflammation pathways in the synovium.
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Not all of the covariate variables were proved being a risk factor for synovial inflammation in knee OA. Receiving oral OA medication, the presence of OA in other joint, hyperuricemia and DM were not giving significant effect to the development of synovial inflammation in knee OA (p > 0.05, respectively).
This study was not examining the biomolecular components that hypothetically involved in the signal transduction pathway of COMP and IL-6 in the development of synovial inflammation of knee OA. Further studies are needed to explain whether anti-apoptosis effect of COMP and mitogenic effect of IL-6 play an important role in the development of sinovial inflammation in knee OA.
CONCLUSION
High level of serum COMP and also high level of plasma IL-6 were proved increased the risk of synovial inflammation in knee OA. Knee OA severity and BMI also played a role in the development of synovial inflammation in knee OA.
